drug_type
RELEVANT_DRUG
intervention_type
Biologic (antibody–drug conjugate)
drug_description
An anti-HER2 antibody–drug conjugate that binds HER2 on tumor cells, is internalized, and releases the microtubule toxin MMAE to disrupt microtubules and induce apoptosis; can also trigger antibody-dependent cellular cytotoxicity (ADCC).
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Disitamab Vedotin
drug_category
ANTIBODY DRUG CONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
Humanized anti‑HER2 monoclonal antibody conjugated to the microtubule toxin MMAE. Upon binding HER2 on tumor cells, the complex is internalized and the linker is cleaved to release MMAE, which inhibits tubulin polymerization leading to G2/M arrest and apoptosis; the antibody Fc can also mediate ADCC.
drug_name
Disitamab vedotin (RC48)
nct_id_drug_ref
NCT06001086